The FDA has approved Lumason, an ultrasound enhancing agent, for use in echocardiography to opacify the left ventricular chamber.
Initiation of statin therapy during childhood in patients with familial hypercholesterolemia slows the progression of CIMT and reduces the risk for CVD over 20 years.
The FDA has approved Entresto for the treatment of symptomatic heart failure in pediatric patients.
The current pediatric heart allocation policy has increased congenital heart disease status 1A representation but has not improved waitlist mortality,
Katerzia (amlodipine) Oral Suspension, 1mg/mL is now commercially available.
Ventricular dysfunction that occurs in newborns within 48 hours of life with congenital diaphragmatic hernia is common and may represent an independent indicator of disease severity and associated survival.
Investigators sought to create a risk prediction tool for sudden cardiac death in children with childhood hypertrophic cardiomyopathy.
A significant number of overweight and obese young people who are classified as nonhypertensive by the European Society of Hypertension criteria have high blood pressure and increased cardiovascular risk, according to newer American Academy of Pediatrics guidelines.
Children and young adults treated with amiodarone have a significant likelihood for thyroid dysfunction soon after treatment initiation.
Pregnant women living near more oil and natural gas development activity have a greater chance of giving birth to children with congenital heart defects.